Skip to main content

Table 4 Crude and adjusted Hazards Ratios for Carcinosarcoma Overall survival (OS) estimated by univariate analysis and multivariate analysis

From: The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma

Clinicopathological features Univariate analysis Multivariate analysis  
HR 95%CI p-value HR 95%CI p-value
Age 1.02 0.98–1.07 0.307 1.03 0.98–1.08 0.157
Stage (I/II vs III/IV) 0.28 0.11–0.71 0.008   
Residual disease (R1/2 vs R0) 3.83 1.92–7.62 0.001 2.87 1.40–5.89 0.003
Adjuvant radiotherapy (Yes vs No) 0.53 0.27–1.05 0.068 0.64 0.32–1.28 0.214
LVI (present vs absent) 1.05 0.47–2.35 0.900 0.99 0.44–2.22 0.985
Histological subtype (Homologous vs Heterologous) 0.84 0.38–1.87 0.671 0.90 0.40–2.01 0.806
CD3_E (high vs low) 0.52 0.27–0.99 0.047 0.65 0.33–1.25 0.200
CD3_S (high vs low) 0.54 0.16–1.79 0.315 0.73 0.22–2.42 0.605
CD4_E (high vs low) 0.52 0.26–1.01 0.054 0.56 0.28–1.11 0.972
CD4_S (high vs low) 0.66 0.32–1.33 0.241 0.60 0.30–1.22 0.160
CD8_E (high vs low) 0.69 0.35–1.39 0.301 0.60 0.29–1.23 0.163
CD8_S (high vs low) 0.77 0.37–1.59 0.478 0.61 0.29–1.28 0.193
FOXP3_E (high vs low) 0.46 0.20–1.06 0.069 0.43 0.18–1.01 0.052
FOXP3_S (high vs low) 0.24 0.06–0.99 0.048 0.26 0.06–1.09 0.066
PD-1_E (high vs low) 0.33 0.16–0.68 0.002 0.39 0.19–0.81 0.011
PD-1_S (high vs low) 0.46 0.19–1.10 0.080 0.52 0.22–1.27 0.152
PD-L1_E (high vs low) 0.54 0.28–1.03 0.062 0.49 0.25–0.96 0.037
PD-L1_S (high vs low) 0.34 0.14–0.81 0.015 0.37 0.15–0.90 0.028
PD-L2_E (high vs low) 0.56 0.24–1.29 0.173 0.76 0.32–1.77 0.519
PD-L2_S (high vs low) 0.44 0.13–1.44 0.174 0.41 0.12–1.35 0.144
CD4/FOXP3_E ratio (high vs low) 0.67 0.36–1.27 0.223 0.76 0.40–1.45 0.407
CD4/FOXP3_S ratio (high vs low) 1.83 0.92–3.65 0.086 2.04 1.02–4.09 0.043
CD8/FOXP3_E ratio (high vs low) 0.68 0.35–1.33 0.262 0.79 0.40–1.57 0.506
CD8/FOXP3_S ratio (high vs low) 2.22 1.14–4.29 0.018 1.91 0.98–3.73 0.058
CD8/CD4_E ratio (high vs low) 0.69 0.27–1.78 0.446 0.58 0.23–1.51 0.268
CD8/CD4_S ratio (high vs low) 0.98 0.39–2.53 0.969 1.16 0.45–3.01 0.754
  1. All variables were adjusted for staging in multivariate analysis. Significant P-values are emboldened
  2. LVI Lymphovascular Invasion, E Epithelial Component, S Sarcomatous Component, ER Estrogen Receptor, PR Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death-Ligand 1, PD-L2 Programmed Death-Ligand 2